These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 18849561

  • 1. Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy.
    Wiese D, Lashner B, Seidner D.
    Nutr Clin Pract; 2008; 23(5):551-6. PubMed ID: 18849561
    [Abstract] [Full Text] [Related]

  • 2. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone.
    Azcue M, Rashid M, Griffiths A, Pencharz PB.
    Gut; 1997 Aug; 41(2):203-8. PubMed ID: 9301499
    [Abstract] [Full Text] [Related]

  • 3. Impact of Disease Activity on Resting Energy Expenditure and Body Composition in Adult Crohn's Disease: A Prospective Longitudinal Assessment.
    Gong J, Zuo L, Guo Z, Zhang L, Li Y, Gu L, Zhao J, Cao L, Zhu W, Li N, Li J.
    JPEN J Parenter Enteral Nutr; 2015 Aug; 39(6):713-8. PubMed ID: 24668997
    [Abstract] [Full Text] [Related]

  • 4. Malabsorption is a major contributor to underweight in Crohn's disease patients in remission.
    Vaisman N, Dotan I, Halack A, Niv E.
    Nutrition; 2006 Sep; 22(9):855-9. PubMed ID: 16928471
    [Abstract] [Full Text] [Related]

  • 5. Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients.
    Diamanti A, Basso MS, Gambarara M, Papadatou B, Bracci F, Noto C, Castro M.
    Int J Colorectal Dis; 2009 Jan; 24(1):19-25. PubMed ID: 18797887
    [Abstract] [Full Text] [Related]

  • 6. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
    Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF.
    Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
    [Abstract] [Full Text] [Related]

  • 7. The Effect of anti-TNFα Induction Therapy on the Nutritional Status and Dietary Intake in Inflammatory Bowel Disease.
    Csontos ÁA, Molnár A, Piri Z, Katona B, Dakó S, Pálfi E, Miheller P.
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):49-56. PubMed ID: 27014753
    [Abstract] [Full Text] [Related]

  • 8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 9. Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy.
    Emerenziani S, Biancone L, Guarino MPL, Balestrieri P, Stasi E, Ribolsi M, Rescio MP, Altomare A, Cocca S, Pallone F, Cicala M.
    Dig Liver Dis; 2017 May; 49(5):495-499. PubMed ID: 28096060
    [Abstract] [Full Text] [Related]

  • 10. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
    Nakahigashi M, Yamamoto T.
    Cytokine; 2011 Nov; 56(2):531-5. PubMed ID: 21820319
    [Abstract] [Full Text] [Related]

  • 11. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 12. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.
    Lönnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM.
    Scand J Gastroenterol; 2011 Apr 10; 46(4):420-7. PubMed ID: 21114432
    [Abstract] [Full Text] [Related]

  • 13. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
    Van Assche G, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, Vanbeckevoort D, Meunier P, Tolan D, Ernst O, Rutgeerts P, Vermeire S, Aerden I, Oortwijn A, Ochsenkühn T.
    J Crohns Colitis; 2013 Dec 10; 7(12):950-7. PubMed ID: 23411006
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
    Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J.
    J Crohns Colitis; 2012 Mar 10; 6(2):143-53. PubMed ID: 22325168
    [Abstract] [Full Text] [Related]

  • 15. Impact of enteral nutrition on energy metabolism in patients with Crohn's disease.
    Zhao J, Dong JN, Gong JF, Wang HG, Li Y, Zhang L, Zuo LG, Feng Y, Gu LL, Li N, Li JS, Zhu WM.
    World J Gastroenterol; 2015 Jan 28; 21(4):1299-304. PubMed ID: 25632205
    [Abstract] [Full Text] [Related]

  • 16. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.
    Sumi R, Nakajima K, Iijima H, Wasa M, Shinzaki S, Nezu R, Inoue Y, Ito T.
    Surg Today; 2016 Aug 28; 46(8):922-9. PubMed ID: 26438200
    [Abstract] [Full Text] [Related]

  • 17. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D, Kökönyei G, Arató A, Dezsőfi A, Molnár K, Müller KE, Lakatos PL, Papp M, Lovász BD, Golovics PA, Cseh A, Veres G.
    J Crohns Colitis; 2014 Aug 28; 8(8):747-55. PubMed ID: 24434181
    [Abstract] [Full Text] [Related]

  • 18. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E, GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives).
    J Crohns Colitis; 2013 Dec 28; 7(12):e678-83. PubMed ID: 23845231
    [Abstract] [Full Text] [Related]

  • 19. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L, Schaper L, Buning C, Hengstermann S, Koernicke T, Tillinger W, Guglielmi FW, Norman K, Buhner S, Ockenga J, Pirlich M, Lochs H.
    Nutrition; 2008 Dec 28; 24(7-8):694-702. PubMed ID: 18499398
    [Abstract] [Full Text] [Related]

  • 20. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease.
    Steiner SJ, Pfefferkorn MD, Fitzgerald JF, Denne SC.
    Pediatr Res; 2008 Dec 28; 64(6):673-6. PubMed ID: 18679167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.